Beijing Konruns Pharmaceutical Co Ltd
SSE:603590
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Beijing Konruns Pharmaceutical Co Ltd
SSE:603590
|
CN |
|
TD Power Systems Ltd
NSE:TDPOWERSYS
|
IN |
|
UFO Moviez India Ltd
NSE:UFO
|
IN |
|
MotorCycle Holdings Ltd
ASX:MTO
|
AU |
|
Investec PLC
LSE:INVP
|
UK |
|
Oruka Therapeutics Inc
NASDAQ:ORKA
|
US |
|
Tasman Resources Ltd
ASX:TAS
|
AU |
|
X
|
Xiangtan Electric Manufacturing Co Ltd
SSE:600416
|
CN |
|
Urban Jakarta Propertindo Tbk PT
IDX:URBN
|
ID |
|
D
|
Dongyue Group Ltd
HKEX:189
|
CN |
|
M
|
Maxicity Holdings Ltd
HKEX:2295
|
HK |
|
Nyssa Corporation Ltd
BSE:504378
|
IN |
|
Aktia Bank Abp
LSE:0QF8
|
FI |
Beijing Konruns Pharmaceutical Co Ltd
Beijing Konruns Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of new drugs, with a focus on new special drugs. The company is headquartered in Beijing, Beijing and currently employs 473 full-time employees. The company went IPO on 2018-08-27. The firm's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Company’s present products under research include a range of innovative and generic drugs for tumors and blood. The firm mainly distributes its products in the domestic market.
Beijing Konruns Pharmaceutical Co., Ltd. engages in the research, development, production, and marketing of new drugs, with a focus on new special drugs. The company is headquartered in Beijing, Beijing and currently employs 473 full-time employees. The company went IPO on 2018-08-27. The firm's main product Suling belongs to the haemocoagulase drug that activates the coagulation process, which is mainly used for hemostasis of superficial wound bleeding in surgical operations as well as the bleeding caused by postoperative, trauma and disease. The Company’s present products under research include a range of innovative and generic drugs for tumors and blood. The firm mainly distributes its products in the domestic market.
